Rita A. Karachun - May 1, 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Rita Karachun
Stock symbol
MRK
Transactions as of
May 1, 2022
Transactions value $
$54,101
Form type
4
Date filed
5/3/2022, 04:17 PM
Previous filing
Feb 28, 2022
Next filing
May 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $82.3K +928 +2.36% $88.69 40.2K May 1, 2022 Direct
transaction MRK Common Stock Tax liability -$28.2K -318 -0.79% $88.69 39.9K May 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Restricted Stock Unit Options Exercise $0 -928 -49.95% $0.00 930 May 1, 2022 Common Stock 928 Direct F2, F3, F4

Explanation of Responses:

Id Content
F1 Holdings include shares acquired in dividend reinvestment transactions.
F2 Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F3 Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
F4 These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.